Lymphoma, T-Cell, Peripheral Clinical Trials

Completed

A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma

NCT00426764

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations: Moore UCSD Cancer Center La Jolla, California, United States

UCLA Division of Hematology Oncology Los Angeles, California, United States

University of California, San Francisco San Francisco, California, United States

Rocky Mountain Cancer Centers-Aurora Aurora, Colorado, United States

View all 90 locations

View Trial Details

Completed

Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies

NCT00040846

Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), +164 more
Locations: Presbyterian - Saint Lukes Medical Center - Health One Denver, Colorado, United States

Huntsman Cancer Institute/University of Utah Salt Lake City, Utah, United States

LDS Hospital Salt Lake City, Utah, United States

VA Puget Sound Health Care System Seattle, Washington, United States

View Trial Details

Completed

Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer

NCT00089011

Conditions: Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, +250 more
Locations: Huntsman Cancer Institute/University of Utah Salt Lake City, Utah, United States

LDS Hospital Salt Lake City, Utah, United States

VA Puget Sound Health Care System Seattle, Washington, United States

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium Seattle, Washington, United States

View Trial Details

Completed

Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies

NCT00014235

Conditions: Acute Myeloid Leukemia/Transient Myeloproliferative Disorder, Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, +159 more
Locations: University of Arizona Health Sciences Center Tucson, Arizona, United States

City of Hope Medical Center Duarte, California, United States

Stanford University Hospitals and Clinics Stanford, California, United States

OHSU Knight Cancer Institute Portland, Oregon, United States

View Trial Details

Completed

Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer

NCT00006251

Conditions: Acute Undifferentiated Leukemia, Adenocarcinoma, Adult Nasal Type Extranodal NK/T-cell Lymphoma, +152 more
Locations: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium Seattle, Washington, United States

University of Torino Torino, Italy

View Trial Details

Completed

Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant

NCT00078858

Conditions: Accelerated Phase Chronic Myelogenous Leukemia, Adenocarcinoma, Adult Acute Lymphoblastic Leukemia in Remission, +220 more
Locations: Stanford University Hospitals and Clinics Stanford, California, United States

Rocky Mountain Cancer Centers-Midtown Denver, Colorado, United States

Emory University/Winship Cancer Institute Atlanta, Georgia, United States

OHSU Knight Cancer Institute Portland, Oregon, United States

View Trial Details

Completed

Allo-hNHL (FluBuCy)

NCT00785330

Conditions: Disease Attributes, Graft vs Host Disease, Hemic and Lymphatic Diseases, +16 more
Locations: Universitätsklinikum Heidelberg Heidelberg, Baden-Würtenberg, Germany

Universitätsklinikum Marburg Marburg, Hesse, Germany

Universitätsklinikum und Poliklinik Homburg, Saarland, Germany

University Hospital Goettingen Göttingen, Germany

View Trial Details

Completed

Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma

NCT02567656

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations: City of Hope Duarte, California, United States

Chao Family Comprehensive Cancer Center University of California Irvine Orange, California, United States

University of Colorado Cancer Center Aurora, Colorado, United States

Emory University School of Medicine Atlanta, Georgia, United States

View Trial Details

Completed

Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry

NCT01110733

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations: DCH Cancer Treatment Center Tuscaloosa, Alabama, United States

Arizona Cancer Center Tucson, Arizona, United States

Genesis Cancer Center Hot Springs, Arkansas, United States

University of Arkansas for Medical Sciences Little Rock, Arkansas, United States

View all 68 locations

View Trial Details

Completed

Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies

NCT00481871

Conditions: B-cell Lymphoma, Blood Protein Disorders, Cardiovascular Diseases, +33 more
Locations: University of California at Los Angeles Los Angeles, California, United States

Stanford University School of Medicine Stanford, California, United States

Rocky Mountain Cancer Center Denver, Colorado, United States

University of Chicago Hospital Chicago, Illinois, United States

View all 15 locations

View Trial Details

Lymphoma, T-Cell, Peripheral

Lymphoma, T-Cell, Peripheral trial results

Related conditions